South and Central America Pharmaceutical Fill and Finish Outsourcing Market

Market Introduction

The pharmaceutical fill and finish outsourcing are more inclined towards contract manufacturing. There are several types of contract manufacturing for pharmaceuticals as well as for biotechnology products that involve partial contract manufacturing and complete manufacturing of pharmaceuticals and biotechnology products.

Moreover, the increase in demand for biopharmaceutical drugs, growing clinical developments, and development of biologics and biosimilars is driving the market’s growth. However, complex processes and high cost of production critically impacts the growth of the market.

The pandemic has become the largest challenge to this region, as they are low-cost regions. For instance, due to the high uncertainty of the spread of COVID-19, the impact on Latin America is expected to be severe, given the continent’s exposure to China. These regions are widely dependent on the import of pharmaceutical and biopharmaceutical products. The lockdown situation in many countries has resulted in no trade in foreign countries. Thus, the countries in the South and Central America have started producing API in their domestic market. However, the cost of production was a challenge for several countries. According to the Brazilian Association of Generic Medicines Industries (PróGenlicos), 75% of the pharmaceutical product is done domestically. However, it is widely dependent on the imports of APIs. The rise in the dollar has created a vital challenge for the manufacturers in the country. Therefore, the government is collaborating with the private market player to supply vaccines against COVID–19.

Market Overview and Dynamics

The South & Central America pharmaceutical fill and finish outsourcing market is expected to reach US$ 203.3 million by 2028 from US$ 132.9 million in 2021. The market is estimated to grow at a CAGR of 6.3% from 2021–2028. Pharmaceutical drug manufacturers collaborate with contract service providers to leverage their experience and expertise in the latest fill finish technologies. Currently, over 115 companies are actively providing services for the fill finish of biologics. Many service providers have also acquired other players in the recent past to enhance their service offerings. For instance, Sanofi has outsourced the manufacturing of its biologics to Boehringer Ingelheim. Moreover, AbbVie operations have successfully developed and delivered drug products for more than 130 years; over 14 million small-volume parenteral (SVPs) are filled annually across AbbVie’s network, and the filled products are distributed over 175 countries.

Key Market Segments

In terms of state of finished products, the liquid segment accounted for the largest share of the South & Central America pharmaceutical fill and finish outsourcing market in 2020. In terms of content, the organic substances isolated from microorganism’s segment accounted for the largest share of the South & Central America pharmaceutical fill and finish outsourcing market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the pharmaceutical fill and finish outsourcing market in South & Central America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott, TEVA PHARMACEUTICAL INDUSTRIES LTD, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd, Piramal Enterprises Ltd., Cytovance Biologics, Thermo Fisher Scientific Inc. (Patheon N.V), and Boehringer Ingelheim International GmbH.

Reasons to Buy Report

• To understand the South & Central America pharmaceutical fill and finish outsourcing market landscape and identify market segments that are likely to guarantee a strong return
• To comprehend the ever-changing market landscape and stay ahead in competition
• To efficiently plan merger and acquisition, and partnership deals in the South & Central America pharmaceutical fill and finish outsourcing market by identifying segments with the most promising probable sales
• To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
• To obtain market revenue forecast of the South & Central America pharmaceutical fill and finish outsourcing market based on various segments for the period 2021–2028

SOUTH & CENTRAL AMERICA PHARMACEUTICAL FILL AND FINISH OUTSOURCING MARKET SEGMENTATION

By State of Finished Product

•             Solids

•          Semi-Liquid

•          Liquid

By Content

•             Organic Substances Isolated from Animal Origin

•          Organic Substances Isolated from Microorganisms

•          Inorganic Substances

By Country

• South & Central America
• Brazil
• Argentina
• Rest of South & Central America

Companies Mentioned

• Abbott
• TEVA PHARMACEUTICAL INDUSTRIES LTD
• Dr. Reddy's Laboratories
• Sun Pharmaceutical Industries Ltd
• Piramal Enterprises Ltd.
• Cytovance Biologics
• Thermo Fisher Scientific Inc. (Patheon N.V)
• Boehringer Ingelheim International GmbH      

South and Central America Pharmaceutical Fill and Finish Outsourcing Market Strategic Insights

South and Central America Pharmaceutical Fill and Finish Outsourcing Market Segmentation Analysis

South and Central America Pharmaceutical Fill and Finish Outsourcing Market Report Highlights

South and Central America Pharmaceutical Fill and Finish Outsourcing Report Scope

South and Central America Pharmaceutical Fill and Finish Outsourcing Market Country and Regional Insights